- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05974930
Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction (ULTRA-STEMI)
Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction: the ULTRA-STEMI Trial
The main goal of the ULTRA-STEMI trial is to investigate the prognostic impact of IVUS-guided PCI in patients with STEMI and correlate IVUS measurements with clinical, procedural, imaging and follow-up outcomes of interest.
Study participants will undergo primary PCI as per standardized procedures; IVUS will be performed at baseline, post-intervention and post-optimization. Manual thrombus aspiration will be performed according to clinical indications. The aspirated thrombi will be collected and scanned with micro-computed tomography (micro-CT). Also, angiographic and peri-procedural data will be gathered. Post-PCI instantaneous wave-free ratio (IFR) will also be performed to assess the severity of the residual coronary-artery stenosis, if any. All patients will be followed up for at least12 months for the adjudication of major adverse cardiovascular events.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Georgios Kassimis, MD, PhD
- Phone Number: +306936693916
- Email: gksup@yahoo.gr
Study Contact Backup
- Name: Efstratios Karagiannidis, MD, PhD
- Phone Number: +306938943309
- Email: stratoskarag@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with acute STEMI undergoing primary PCI within 12 hours of symptom onset according to the 4th universal definition of myocardial infarction.
- Age >18 years
- Individuals willing to voluntarily sign the consent and data protection forms before their inclusion in the clinical study.
Exclusion Criteria:
- Patients presenting with cardiogenic shock
- Patients with a known contraindication for primary PCI
- Pregnancy
- Presentation ≥12 hours after symptom onset
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with STEMI undergoing IVUS-guided primary PCI
The ULTRA-STEMI trial will include consecutive patients with STEMI undergoing IVUS-guided primary PCI.
All participants will undergo: IVUS intra-coronary imaging at baseline-, post-intervention and post-optimization.
If manual thrombus aspiration is needed, the aspirated thrombotic material will be collected to be micro-CT scanned.
Post-PCI iFR will be also performed in each participant.
Clinical, angiographic and peri-procedural data will be collected.
Each participant will be subject to telephone follow-up at 1, 6 and 12 months.
|
Eagle Eye Platinum Intravascular ultrasound (IVUS) will be used to assess intra-coronary plaque, thrombus or stenosis in patients with STEMI.
The device is FDA- and EMA-approved and routinely used in clinical practice.
Quantitative and qualitative IVUS parameters will be collected and recorded for all participants to be correlated with clinical, imaging and angiographic outcomes of interest.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of "Target vessel failure" at 12 months of follow-up in association with IVUS measurements
Time Frame: 2 years
|
Follow-up will be obtained using online patient-reported outcome measurements by email or standardized telephone calls at 30 days, 6 months and 12 months after the procedure.
Primary follow-up outcome of interest is the composite endpoint of target vessel failure (cardiac death, new-onset heart failure, target vessel myocardial infarction, clinically driven target vessel revascularization or target lesion revascularization).
|
2 years
|
All-cause mortality at 12 months of follow-up in association with IVUS measurements
Time Frame: 2 years
|
Co-primary study outcome will be the investigation of all-cause mortality (i.e., death from any cause) after hospitalization and during follow-up.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In-hospital (post-PCI) adverse events in association with IVUS measurements
Time Frame: 2 years
|
The composite endpoint of in-hospital (post-PCI) adverse events includes: cardiac tamponade, need for CABG, shock, in-hospital mortality, acute kidney failure, bleeding, stroke.
|
2 years
|
Pre-procedural angiographic outcomes in association with IVUS measurements
Time Frame: 2 years
|
Pre-procedural Thrombolysis in myocardial infarction (TIMI) flow, thrombus burden classification, culprit vessel, number of diseased vessels, and the SYNergy between percutaneous intervention with TAXus DES and cardiac surgery (SYNTAX) score will be recorded and associated with pre-procedural IVUS measurements.
Higher SYNTAX score and lower TIMI flow represent greater obstruction in the diseased vessels.
|
2 years
|
Post-procedural angiographic outcomes in association with IVUS measurements
Time Frame: 2 years
|
Post-procedural TIMI flow, angiographically evident residual thrombus, no-reflow phenomenon, myocardial blush grade, and distal embolization will be recorded and associated with IVUS measurements.
|
2 years
|
Post-PCI iFR measurement in association with IVUS measurements
Time Frame: 2 years
|
iFR=ratio of distal coronary pressure (Pd) to the aortic pressure (Pa) during an isolated period during diastole.
|
2 years
|
Microtomographic thrombus volume in association with IVUS measurements
Time Frame: 2 years
|
Micro-CT derived volume of the extracted thrombotic material will be correlated with IVUS measurements.
|
2 years
|
Microtomographic thrombus porosity in association with IVUS measurements
Time Frame: 2 years
|
Micro-CT derived porosity of the extracted thrombotic material will be correlated with IVUS measurements.
|
2 years
|
Microtomographic thrombus density in association with IVUS measurements
Time Frame: 2 years
|
Micro-CT derived density of the extracted thrombotic material will be correlated with IVUS measurements.
|
2 years
|
Νumber and type of stents in association with IVUS measurements
Time Frame: 2 years
|
Νumber and type of stents used will be recorded and associated with IVUS measurements.
|
2 years
|
Stent length and diameter in association with IVUS measurements
Time Frame: 2 years
|
Stent length and diameter will be recorded and associated with IVUS measurements.
|
2 years
|
Contrast volume in association with IVUS measurements
Time Frame: 2 years
|
Volume of the contrast used will be recorded and associated with IVUS measurements.
|
2 years
|
Radiation dose in association with IVUS measurements
Time Frame: 2 years
|
Peri-procedural radiation dose will be recorded and associated with IVUS measurements.
|
2 years
|
Procedural duration in association with IVUS measurements
Time Frame: 2 years
|
Procedural duration will be recorded and associated with IVUS measurements.
|
2 years
|
Post-PCI stent underexpansion, deformation or malapposition in association with baseline IVUS measurements
Time Frame: 2 years
|
Stent underexpansion, deformation or malapposition (yes/no) will be recorded and associated with baseline IVUS measurements.
|
2 years
|
Post-PCI edge dissection in association with baseline IVUS measurements
Time Frame: 2 years
|
Edge dissection (yes/no) will be recorded and associated with baseline IVUS measurements.
|
2 years
|
Post-PCI high plaque burden at stent edges, residual focal lesions or tissue protrusion through the stent struts in association with baseline IVUS measurements
Time Frame: 2 years
|
High plaque burden at stent edges, residual focal lesions or tissue protrusion through the stent struts (yes/no) will be recorded and associated with baseline IVUS measurements.
|
2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Georgios Kassimis, MD, PhD, 2ND Cardiology Department, Hippokrateion General Hospital of Thessaloniki, Greece
Publications and helpful links
General Publications
- Groenland FTW, Mahmoud KD, Neleman T, Ziedses des Plantes AC, Scoccia A, Ligthart J, Witberg KT, Nuis RJ, den Dekker WK, Wilschut JM, Diletti R, Zijlstra F, Kardys I, Cummins P, Van Mieghem NM, Daemen J. Tissue characterisation and primary percutaneous coronary intervention guidance using intravascular ultrasound: rationale and design of the SPECTRUM study. Open Heart. 2022 Apr;9(1):e001955. doi: 10.1136/openhrt-2021-001955.
- Karagiannidis E, Papazoglou AS, Sofidis G, Chatzinikolaou E, Keklikoglou K, Panteris E, Kartas A, Stalikas N, Zegkos T, Girtovitis F, Moysidis DV, Stefanopoulos L, Koupidis K, Hadjimiltiades S, Giannakoulas G, Arvanitidis C, Michaelson JS, Karvounis H, Sianos G. Micro-CT-Based Quantification of Extracted Thrombus Burden Characteristics and Association With Angiographic Outcomes in Patients With ST-Elevation Myocardial Infarction: The QUEST-STEMI Study. Front Cardiovasc Med. 2021 Apr 21;8:646064. doi: 10.3389/fcvm.2021.646064. eCollection 2021.
- Didagelos M, Pagiantza A, Zegkos T, Zarra K, Angelopoulos V, Kouparanis A, Peteinidou E, Kassimis G, Karvounis H, Ziakas A. Low Molecular Weight Heparin in Improving RAO After Transradial Coronary Catheterization: The LOW-RAO Randomized Study. JACC Cardiovasc Interv. 2022 Aug 22;15(16):1686-1688. doi: 10.1016/j.jcin.2022.05.047. Epub 2022 Jul 27. No abstract available.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69589
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on STEMI
-
Clinical Operations WCN B.V.SanofiEnrolling by invitationAtherosclerotic Cardiovascular Disease | STEMI | Non STEMINetherlands
-
Kingston UniversityUniversity of Leeds; Swansea University; London Ambulance Service; West Midlands... and other collaboratorsCompletedAcute Coronary Syndrome | STEMI | Non STEMIUnited Kingdom
-
Karolinska InstitutetEnrolling by invitation
-
Beijing Friendship HospitalActive, not recruiting
-
University of OradeaCompleted
-
Prolocor, IncRecruitingSTEMI | NSTEMIUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedPrimary PCI - STEMIFrance
-
VesalioRecruitingSegment Elevation Myocardial Infarction (STEMI)Switzerland
-
University of PisaCompleted
-
AstraZenecaCompletedMyocardial Infarction | Segment Elevation Myocardial Infarction (STEMI)Australia, France, Italy, Spain, United Kingdom, Sweden, Germany, Hungary, Denmark, Austria, Canada, Netherlands, Algeria
Clinical Trials on IVUS imaging for primary PCI guidance
-
Yonsei UniversityCompletedCoronary Artery DiseaseKorea, Republic of
-
Second Affiliated Hospital, School of Medicine,...Zhejiang University; First Affiliated Hospital of Wenzhou Medical University; Taizhou First People's Hospital and other collaboratorsAvailableST Elevation Myocardial InfarctionChina
-
Chonnam National University HospitalRecruitingAtherosclerosis | Ischemic Heart DiseaseKorea, Republic of
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompleted
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaActive, not recruitingLow or Intermediate Risk Prostate CancerCanada
-
Kansas City Heart Rhythm Research FoundationRecruitingStroke | Atrial FibrillationUnited States
-
Samsung Medical CenterCompletedCoronary Artery Disease | AtherosclerosisKorea, Republic of
-
Yonsei UniversityCardioVascular Research Foundation, KoreaCompleted
-
University of WashingtonNational Institute on Drug Abuse (NIDA); Kaiser PermanenteCompleted